References
- Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41:1–10.
- Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respir Med. 2012;106(4):473–492.
- Del Rivero J, Enewold L, Thomas A. Metastatic lung cancer in the age of targeted therapy: improving long-term survival. Transl Lung Cancer Res. 2016;5(6):727–730.
- Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. Cancer Treat Res. 2016;170:47–75.
- Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol. 2010;7(9):487–493.
- Clausen MM, Langer SW. Improving the prognosis for lung cancer patients. Acta Oncol. 2019;58(8):1077–1078.
- Fahim A, Crooks MG, Wilmot R, et al. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis. Respirology. 2012;17(8):1247–1252.
- Lin HY, Chin YT, Yang YC, et al. Thyroid hormone, cancer, and apoptosis. Compr Physiol. 2016;6:1221–1237.
- Krashin E, Piekielko-Witkowska A, Ellis M, et al. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol. 2019;10:59.
- Ko AH, Wang F, Holly EA. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay area, California. Cancer Causes Control. 2007;18(8):809–819.
- Mazzoccoli G, Pazienza V, Piepoli A, et al. Alteration of hypothalamic-pituitary-thyroid axis function in non-small-cell lung cancer patients. Integr Cancer Ther. 2012;11(4):327–336.
- Chen YK, Lin CL, Chang YJ, et al. Cancer risk in patients with graves’ disease: a nationwide cohort study. Thyroid. 2013;23:879–884.
- Lehrer S, Diamond EJ, Bajwa AM, et al. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Prostate Cancer Prostatic Dis. 2001;4(4):232–234.
- Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011;117(3):534–544.
- Hellevik AI, Asvold BO, Bjoro T, et al. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev. 2009;18:570–574.
- Khan SR, Chaker L, Ruiter R, et al. Thyroid function and cancer risk: the Rotterdam study. J Clin Endocrinol Metab. 2016;101:5030–5036.
- Mohamed F, Abdelaziz AO, Kasem AH, et al. Thyroid hormone receptor alpha1 acts as a new squamous cell lung cancer diagnostic marker and poor prognosis predictor. Sci Rep. 2021;11(1):7944.
- Meng R, Tang HY, Westfall J, et al. Crosstalk between integrin alphavbeta3 and estrogen receptor-alpha is involved in thyroid hormone-induced proliferation in human lung carcinoma cells. PLoS One. 2011;6:e27547.
- Liu YC, Yeh CT, Lin KH. Molecular functions of thyroid hormone signaling in regulation of cancer progression and anti-apoptosis. Int J Mol Sci. 2019;20:4986.
- Latteyer S, Christoph S, Theurer S, et al. Thyroxine promotes lung cancer growth in an orthotopic mouse model. Endocr Relat Cancer. 2019;26:565–574.